Report from the American Society of Transplantation on frailty in solid organ transplantation by Kobashigawa, Jon et al.
984  |   amjtransplant.com Am J Transplant. 2019;19:984–994.© 2018 The American Society of Transplantation 
and the American Society of Transplant Surgeons
 
Received: 20 September 2018  |  Revised: 6 November 2018  |  Accepted: 24 November 2018
DOI: 10.1111/ajt.15198
M E E T I N G  R E P O R T
Report from the American Society of Transplantation on frailty 
in solid organ transplantation
Jon Kobashigawa1 | Darshana Dadhania2 | Sangeeta Bhorade3 | Deborah Adey4 |  
Joseph Berger5 | Geetha Bhat6 | Marie Budev7 | Andres Duarte‐Rojo8 | Michael Dunn9 |  
Shelley Hall10 | Meera N. Harhay11  | Kirsten L. Johansen4 | Susan Joseph10 |  
Cassie C. Kennedy12 | Evan Kransdorf1  | Krista L. Lentine13 | Raymond J. Lynch14 |  
Mara McAdams‐DeMarco15  | Shunji Nagai16  | Michael Olymbios1 | Jignesh Patel1 |  
Sean Pinney17 | Joanna Schaenman18 | Dorry L. Segev15 | Palak Shah19 | Lianne G. Singer20  |  
Jonathan P. Singer4  | Christopher Sonnenday21  | Puneeta Tandon22 | Elliot Tapper21 |  
Stefan G. Tullius23 | Michael Wilson12 | Martin Zamora24 | Jennifer C. Lai4
1Cedars‐Sinai Smidt Heart Institute, Los Angeles, California
2Weill Cornell Medicine, New York, New York
3Northwestern University, Chicago, Illinois
4University of California at San Francisco, San Francisco, California
5University of Texas Southwestern Medical Center, Dallas, Texas
6Advocate Christ Medical Center, Oak Lawn, Illinois
7Cleveland Clinic, Cleveland, Ohio
8University of Arkansas, Little Rock, Arkansas
9University of Pittsburgh, Pittsburgh, Pennsylvania
10Baylor University, Dallas, Texas
11Drexel University, Philadelphia, Pennsylvania
12Mayo Clinic, Rochester, Minnesota
13St. Louis University, Saint Louis, Missouri
14Emory University, Atlanta, Georgia
15Johns Hopkins University, Baltimore, Maryland
16Henry Ford Hospital, Detroit, Michigan
17Mount Sinai Hospital, New York, New York
18University of California, Los Angeles, California
19Inova Heart and Vascular Institute, Falls Church, Virginia
20University of Toronto, Toronto, Ontario, Canada
21University of Michigan, Ann Arbor, Michigan
22University of Alberta, Edmonton, Alberta, Canada
23Division of Transplant Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
24University of Colorado, Denver, Colorado
Abbreviations: ADL, activities of daily living; ASN, American Society of Nephrology; AST, American Society of Transplantation; ASTS, American Society of Transplant Surgeons; CKD, 
chronic kidney disease; CST, Canadian Society of Transplantation; CT, computed tomography; DASI, Duke activity status index; DEXA, dual energy X‐ray absorptiometry; ESRD, end‐stage 
renal disease; FFP, fried frailty phenotype; HR, hazard ratio; HRQO, health‐related quality of life; MCSD, mechanical circulatory support device; MELDNa, model for end‐stage liver disease 




     |  985KOBASHIGAWA et Al.
A consensus conference on frailty in kidney, liver, heart, and lung transplantation 
sponsored by the American Society of Transplantation (AST) and endorsed by the 
American Society of Nephrology (ASN), the American Society of Transplant Surgeons 
(ASTS), and the Canadian Society of Transplantation (CST) took place on February 
11, 2018 in Phoenix, Arizona. Input from the transplant community through sched-
uled conference calls enabled wide discussion of current concepts in frailty, explora-
tion of best practices for frailty risk assessment of transplant candidates and for 
management after transplant, and development of ideas for future research. A cur-
rent understanding of frailty was compiled by each of the solid organ groups and is 
presented in this paper. Frailty is a common entity in patients with end‐stage organ 
disease who are awaiting organ transplantation, and affects mortality on the waitlist 
and in the posttransplant period. The optimal methods by which frailty should be 
measured in each organ group are yet to be determined, but studies are underway. 
Interventions to reverse frailty vary among organ groups and appear promising. This 
conference achieved its intent to highlight the importance of frailty in organ trans-
plantation and to plant the seeds for further discussion and research in this field.
K E Y W O R D S
clinical research/practice, heart disease, immune regulation, kidney disease, kidney 
transplantation/nephrology, liver disease, liver transplantation/hepatology, lung disease, lung 
transplantation/pulmonology
1  | INTRODUC TION
A consensus conference on frailty in solid organ transplantation 
sponsored by the American Society of Transplantation (AST) and en-
dorsed by the American Society of Nephrology (ASN), the American 
Society of Transplant Surgeons (ASTS) and the Canadian Society of 
Transplantation (CST) took place on February 11, 2018 in Phoenix, 
Arizona. The conference served to update the solid organ transplant 
community on current concepts in frailty, generate ideas for optimal 
metrics of frailty assessment of transplant candidates, and pose per-
tinent questions for future research related to the implications and 
management of frailty in transplantation. Prior to the meeting, a se-
ries of conference calls were organized within each of the four solid 
organ groups (kidney, liver, heart, and lung). During each conference 
call, different topics in frailty were discussed with up to 30 mem-
bers from the respective AST Community of Practice participating in 
each call. Altogether, more than 120 AST members representing 56 
transplant centers participated in these conference call discussions 
(Appendix A). At the conference, 32 AST members representing all 
four solid organs met to discuss the information that was generated 
by each organ group. This paper represents the current understand-
ing of frailty in solid organ transplantation.
Frailty is a pathobiological process characterized by loss of 
physiologic reserve and increased vulnerability to stressors. It is 
an independent domain of risk, overlapping with but distinct from 
comorbidity (such as physiologic aging) and disability; and portends 
worse outcomes for patients with end‐stage organ disease and pa-
tients undergoing solid organ transplantation.1 Identifying potential 
reversible components contributing to frailty associated with organ 
failure could allow for education of transplant candidates and refer-
ring providers, identify opportunities for intervention, optimize tim-
ing for transplantation, and improve outcomes.
Before the conference, attendees were invited to participate in 
an online survey. A total of 257 responses were submitted by phy-
sicians, surgeons and allied health professionals from across the 
solid organ specialties. An overwhelming 98.6% of the respondents 
viewed frailty as a useful concept for evaluating transplant candi-
dates. Further, 93% of the respondents believed that a frailty as-
sessment should be incorporated into the selection process for 
transplant candidates. Common survey question results pertinent to 
all organ groups are presented in Table 1.
2  | PATHOPHYSIOLOGY OF FR AILT Y
Frailty is considered a complex and multifactorial process that is 
characterized by dysregulation of multiple physiological systems 
that cause an altered immune response, neuroendocrine changes, 
and cognitive impairment. Pathophysiological mechanisms of frailty 
and aging somewhat overlap. An important difference between 
chronological aging and frailty is that frailty has the inability to main-
tain homeostasis. Genetic susceptibility, comorbidities, physiological 
aging, and environmental factors, also play a role in the pathophysi-
ology of frailty.1
Frailty symptoms have been linked to disease severity such as 
the model for end‐stage liver disease and sodium (MELDNa) score 
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in liver transplantation.2 Biomarkers for frailty have been suggested, 
based on the concept that aging represents a low‐grade chronic in-
flammatory process, sometimes termed “inflammaging.” IL‐6, TNF‐α, 
CXCL‐10, neopterin, lower CD4:CD8 ratios, higher numbers of mem-
ory T‐cells, and cell‐free mitochondrial DNA are reported specific 
biomarkers of frailty.3-5
Sarcopenia (loss of skeletal muscle mass) may be a precursor 
to the development of frailty and its adverse health outcomes.6 In 
many studies it has been described as measurement of the psoas 
muscle.7-11 Sarcopenia and frailty share similar underlying mecha-
nisms, such as physical inactivity, chronic inflammation, and endo-
crine dysregulation.7,8,12 As with frailty, studies of sarcopenia are 
limited by the lack of universally accepted definitions and methods 
of measurement.13 Sarcopenia, like frailty, may be a risk factor for 
worse outcomes in lung transplant candidates; however, data are 
conflicting, with some studies showing lower pretransplant skeletal 
muscle mass measured radiographically being a risk factor for worse 
outcomes,9,14 and others showing risk for longer hospital stays but 
not mortality.15,16 Identification and early diagnosis of sarcopenia 
and interventions targeting the skeletal muscle may help to prevent 
or manage frailty.10 More information is needed to determine the 
definition and criteria for determination of sarcopenia, the optimal 
method of measurement, and the prognosis of frailty with and with-
out the coexistence of sarcopenia.17,18
3  | FR AILT Y ME A SURES
There are numerous instruments to assess frailty. Most screening 
tools for frailty are based on two concepts: “physical” or “pheno-
typic” frailty, versus “deficit accumulation” or “index” frailty.19
The most extensively validated tool is the Fried Frailty 
Phenotype (FFP)20 consisting of five components, including uninten-
tional weight loss, low physical activity, exhaustion, slow gait speed, 
and weak handgrip strength. The testing takes under 10 minutes to 
administer, is easily implemented, and can be interpreted by non-
geriatricians. According to Fried, a score of 3 to 5 is defined as frail, 
1 to 2 as prefrail, and 0 is nonfrail. A higher score on the FFP has 
been used to predict morbidity and mortality in inpatient and com-
munity‐dwelling populations. Handgrip strength and gait speed, the 
quantitative criteria of the FFP may more objectively assess frailty 
than the other components. Limitations of the FFP criteria are the 
need for hand dynamometer equipment, ability to ambulate and the 
omission of assessment tools such as cognition, mood, and nutrition.
Another widely used approach conceptualizes frailty as an index 
of cumulative deficits. The Frailty Index (Rockwood Accumulation 
of Deficits Index) is based on 30 to 70 deficits measured by clini-
cal symptoms, functional impairments, laboratory findings, disabili-
ties, and comorbidities. The ratio of the number of deficits present 
to the total number of items assessed gives the index score. The 
Frailty Index result gives a more quantitative measure of the severity 
of frailty than the FFP score and may include a wider range of defi-
cits (such as comorbidities and disabilities) not captured by the FFP. 
Although the index may be more time consuming to administer, and 
therefore less practical, it may be more useful for evaluating response 
to  treatment.21 The Short Physical Performance Battery (SPPB), 
a tool to measure lower extremity function that is associated with 
physiologic reserve has also been commonly used to assess frailty 
and has been validated in various organ groups.22‐26 Low muscle mass 
and function (known as sarcopenia) has also been used as an objec-
tive indicator of frailty and can be reliably measured by dual‐energy 
X‐ray absorptiometry (DEXA), or estimated by computed tomogra-
phy (CT), magnetic resonance imaging, or bioimpedance.27 Finally, a 
questionnaire commonly used to assess patient inactivity is the mod-
ified Minnesota Leisure Time Activity scale, which contains activities 
that are likely less relevant to the advanced organ failure population 
who rarely participate in activities such as jogging or bowling.28
4  | CURRENT UNDERSTANDING OF 
FR AILT Y IN E ACH OF THE ORGAN 
TR ANSPL ANT GROUPS
As a result of the pre‐meeting conference calls and breakout ses-
sion at the convening frailty conference, a current understanding of 
frailty was compiled from each of the solid organ groups. What fol-
lows is a summary of these discussions.
4.1 | Frailty considerations in kidney transplantation
In a systematic review of studies on the association of frailty and 
chronic kidney disease (CKD) that included over 36 000 patients, 
Chowdhury et al found that the FFP20 was the most commonly used 
frailty assessment tool, accounting for 72% of the studies, although 
there was substantial heterogeneity in its interpretation.
CKD is associated with frailty and the incidence of frailty in CKD 
increases with progressive decline in kidney function.29 Fitzpatrick 
and colleagues demonstrated that 52% of the dialysis patients were 
frail using the FFP.30 A large, multicenter study of frailty among 
kidney transplant candidates (n = 3938; enrolled at the time of 
evaluation) and kidney transplant recipients (n = 1291; enrolled at 
admission) is currently ongoing. In this cohort, McAdams‐DeMarco 
and colleagues found that 18% of the patients on the waitlist for kid-
ney transplant31 and 20% of the kidney transplant recipients were 
frail by the FFP.32
Additionally, in this large cohort, McAdams‐DeMarco and col-
leagues found that frailty at the time of kidney transplant evaluation 
was associated with a 2.8‐fold higher odds of fair or poor health‐ 
related quality of life (HRQOL) and a 2.9‐fold higher risk of declining 
HRQOL while waiting for kidney transplantation33 and 2.2‐fold in-
creased risk of waitlist mortality.31 Furthermore, frail kidney trans-
plant recipients are at 2.1‐fold increased risk of delirium following 
kidney transplantation34 and a 1.6‐fold higher risk of longer length 
of stay,35.9‐fold higher risk of delayed graft function,26.6‐fold higher 
risk of early hospital readmission,36.3‐fold higher risk of immunosup-
pression intolerance,37 and 2.2‐fold higher risk of mortality.38
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Low physical function assessments and inability to perform ac-
tivities of daily living (ADLs) have both been associated with higher 
risk of mortality in patients with end‐stage renal disease (ESRD).39,40 
Using the Medical Outcomes Study Short Form‐36 (SF‐36) Physical 
Component Scale (PCS) questionnaire to evaluate physical function, 
analysis of the United Network for Organ Sharing (UNOS) registry 
data of 10 875 kidney transplant recipients identified low physi-
cal function as an independent predictor of mortality (HR = 1.7).41 
Lower extremity impairment using SPPB, another objective measure 
related to frailty is also associated with poor outcomes after kidney 
transplant and an increased length of stay for the kidney transplant 
hospitalization.16 In a recent study, the prevalence of lower extrem-
ity impairment was higher in the group of kidney transplant recipi-
ents classified as being frail (70%) compared to the entire cohort of 
frail and nonfrail (47%) kidney transplant recipients.42 Importantly, 
impairment was associated with a 2.3‐fold higher risk of mortality 
independent of the frailty phenotype.
Systematic review has demonstrated that most investigations 
of frailty have focused on developing risk assessment tools (31%), 
studying the etiology of frailty (22%), and developing methods (14%) 
and biomarkers (12%) for frailty assessment.43 Indeed, markers of 
inflammation and serum albumin levels are associated with frailty 
among ESRD patients, but significant variation is observed in the 
patient frailty scores from year to year.44 Strikingly the data suggest 
that nephrologists cannot correctly identify which dialysis patients 
are frail.45 One reason could be that some of the FFP component 
measurement such as unintentional weight loss can be challenging 
in an ESRD patient with fluctuating fluid weight as suggested by the 
Delphi study composed of 42 ESRD providers.46
Small, randomized trials of patients with CKD and ESRD have 
demonstrated the potential benefits of rehabilitation programs to 
prevent or reverse sarcopenia and improve physical function in di-
alysis patients.47-50 Integrated inpatient rehabilitation may help de-
pendent hemodialysis patients regain functional status.51
Key points in kidney transplantation:
1. Frailty is common in patients with CKD (pretransplant and 
posttransplant) and ESRD with numerous negative implications 
for health status.
2. The ideal components of the frailty metric for kidney transplant 
candidates and recipients are unknown; studies to compare met-
rics, harmonize measurements, and identify an ESRD‐specific 
measure of frailty would be of value.
3. Patients identified to be frail may benefit from physical therapy 
and rehabilitation, and additional studies are needed to under-
stand how such interventions affect outcomes in kidney trans-
plant candidates and recipients.
4.2 | Frailty considerations in liver transplantation
Applications of frailty in liver transplantation have largely focused 
on the physical dimension of the frailty construct (eg, FFP), and more 
recently, they have expanded to tools that capture functional capac-
ity and disability. Physical frailty is prevalent in patients with cirrho-
sis: among outpatients, the prevalence of frailty ranged from 17% 
to 35% by the FFP22,52 and was estimated to be 38% by the SPPB22; 
among inpatients, 68% were functionally impaired as defined by the 
Karnofsky Performance Scale ≤70%.53 Frailty has consistently been 
shown to be a critical determinant of liver transplant outcomes, in-
cluding hospitalizations, and mortality both before2,52,54-57 and after 
liver transplantation.53,58‐61
A range of tools to measure frailty and physical function have 
been studied in this population, and recent efforts to standardize 
frailty measurement in liver transplantation have yielded the Liver 
Frailty Index.2 Consisting of handgrip strength, chair stands, and 
balance testing, the Liver Frailty Index was derived specifically to 
capture the construct of physical frailty in liver transplant candi-
dates and is strongly predictive of waitlist mortality. In fact, it more 
accurately classifies waitlist mortality than the MELDNa score 
alone. This metric is easy to administer and scored on a continu-
ous scale, making it well‐suited for the liver transplant setting. We 
advocate for the use of the Liver Frailty Index in the baseline and 
longitudinal assessments of liver transplant patients to standardize 
incorporation of frailty into center‐level transplant decision‐making.
True to the multidimensional construct of frailty, the pathogen-
esis of frailty in patients with cirrhosis is multi‐factorial and includes 
under‐nutrition from inadequate oral intake, low physical activity, 
systemic inflammation, and hypogonadism. Unique to cirrhosis are 
the contributions of hepatic synthetic dysfunction in accelerating 
muscle protein breakdown, as well as the deleterious effects of im-
paired detoxification of ammonia on muscle health.11 Each of these 
factors accelerates the development of sarcopenia, which plays a 
central role in frailty pathogenesis. The prevalence of sarcopenia 
among liver transplant candidates ranges from 22% to 70%.62
Understanding the pathogenesis of cirrhosis‐specific frailty has 
provided multiple targets for intervention, which is rapidly emerg-
ing as the next frontier of frailty research in liver transplantation. In 
patients with cirrhosis, several small trials of exercise interventions, 
some of which have also included dietary counseling have demon-
strated improvements in muscle mass, muscle strength, exercise 
capacity, HRQOL, and reductions in portal hypertension.63 A sin-
gle randomized clinical trial of intramuscular testosterone in hypo-
gonadal men with cirrhosis demonstrated improvements in muscle 
mass, with a trend to increases in strength.64
While data on the topic of rehabilitation prior to liver transplan-
tation are currently limited, early studies are promising, leading to 
the conclusion that physical frailty—or at least some of its compo-
nents—is modifiable in liver transplant candidates. More research 
should focus on developing rehabilitation programs that target 
frailty components with the goal of improving outcomes—including 
both survival and HRQOL—before and after liver transplantation.
Key points in liver transplantation:
1. Frailty is prevalent and a critical determinant of poor 
outcomes.
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2. Frailty measurements should be standardized and performed rou-
tinely in patients undergoing evaluation for liver transplantation.
3. Although subjective screening tools may be useful for quickly 
identifying patients vulnerable to poor outcomes, performance‐
based tools better assess response to interventions and inform 
candidate selection.
4. Poor caloric intake, low physical activity, and muscle depletion are 
integral components of frailty and represent potential targets for 
intervention through rehabilitation programs.
4.3 | Frailty considerations in lung transplantation
There are emerging data suggesting that frailty may be associated 
with greater morbidity and mortality pre‐ and post‐lung transplanta-
tion. Three studies to date have evaluated the prognostic utility of 
frailty in lung transplantation. Singer et al demonstrated that phe-
notypic frailty, utilizing either the FFP or the SPPB was prevalent 
in lung transplant candidates and was associated with disability and 
delisting or death prior to transplant as well as 1‐ and 4‐year mor-
tality after transplant.23,24 Similarly, Wilson and colleagues showed 
that increased cumulative deficits using the frailty deficit index dem-
onstrated a high prevalence of frailty (45% in 102 patients) and was 
independently associated with lower posttransplant survival.65
Measuring frailty before transplant offers the potential for im-
proving risk stratification and refining candidate selection. It is 
important to note that the appropriate frailty measure should ac-
curately quantify risk for the outcome of interest. For example, the 
FFP incorporates elements that are likely to be improved by lung 
transplantation (eg, slowness, weight loss), whereas the cumulative 
frailty deficits index may change less or even worsen with the de-
velopment of new extrapulmonary comorbidities (eg, diabetes, renal 
dysfunction) even after a successful transplant.
Sarcopenia is thought to be a key precursor to the development 
of frailty. In lung transplantation, studies of sarcopenia are limited by 
the lack of a universally accepted definition. Nonetheless, lung trans-
plant candidates and recipients have been shown to have decreased 
muscle mass, strength and function, which are the key components 
of sarcopenia. Data regarding sarcopenia in lung transplantation are 
somewhat conflicting, with some studies showing lower pretrans-
plantation skeletal muscle mass being a risk factor for worse out-
comes9,14 and others not showing a higher risk of mortality among 
patients with low muscle mass.15,16 A systematic review of sarcope-
nia in lung transplantation included 18 studies that have shown that 
fat‐free mass and quadriceps strength were lower than in controls, 
declined further in the early posttransplant period, and then recov-
ered during long‐term follow‐up.66 Therefore, body composition as-
sessed by DEXA or by single‐slice CT or MRI may be useful.
A number of questions remain with respect to the optimal frailty 
measure, applicability of frailty tools for candidate selection, and 
which frailty criteria are most amenable to rehabilitation pre‐ and 
post‐lung transplantation. In a cohort of nontransplanted chronic 
obstructive pulmonary disease patients, phenotypic frailty was 
reversible in those patients who completed pulmonary rehabilita-
tion, suggesting that frail lung transplant candidates could derive 
significant benefit from rehabilitation.67 A small pilot study of a 
home‐based rehabilitation program in lung transplant candidates 
demonstrated that frailty measured by SPPB and FFP improved in 
over half of participants.25 Several smaller studies and one random-
ized, controlled trial evaluating patients receiving pre‐ and post‐lung 
transplant rehabilitation, suggest that there may be some improve-
ment in muscle function (6‐minute walk test and physical activity 
time) and strength (measured by quadriceps torque) by 6 months 
posttransplant.68,69
Several interventions were discussed to improve frailty in candi-
dates for lung transplantation, with the recognition that additional 
studies are needed to assess the benefit of these interventions. 
These interventions included: (1) consultation with nutrition spe-
cialist and consideration of nutritional supplementation; (2) enroll-
ment in a physical therapy program and/or integrated pulmonary 
rehabilitation program; (3) geriatric consultation to identify and im-
prove factors which may be contributing to frailty, eg, polypharmacy, 
cognitive impairment. Social work assessment to optimize social 
support.
Key points in lung transplantation:
1. Phenotypic frailty is prevalent in lung transplant candidates.
2. Increased cumulative deficits are independently associated with 
lower posttransplant survival.
3. Candidate selection is fundamentally dependent on establishing 
the validity of frailty measures and demonstrating their strong 
and independent association with outcomes after lung 
transplantation.
4. Potential interventions to reverse frailty that require further study 
include pulmonary rehabilitation and nutritional supplementation.
4.4 | Frailty considerations in heart transplantation
Within advanced heart failure the prevalence of frailty ranges from 
25% to 78% depending on the instrument and individual criteria 
used to define frailty. Heart failure and frailty share a common set of 
symptoms that can be attributed to either state (eg, fatigue, exhaus-
tion, weight loss).70
Only a few frailty measures have been prospectively assessed in 
patients with heart failure and most have used a modification of the 
FFP.20 Jha and colleagues demonstrated that one‐third of their heart 
failure population was identified as being frail and was independent 
of age, sex, or ejection fraction.71 The 1‐year actuarial survival for 
frail patients was 54% compared to 79% in nonfrail patients. Further, 
nonfrail patients who went on to receive a heart transplant had a 
1‐year posttransplant survival of 100%, compared to 52% in frail pa-
tients. Another tool to measure frailty is sarcopenia of the pectoralis 
muscle on chest CT which has been shown to be highly discrimina-
tory in its ability to predict risk of death after mechanical circulatory 
support device (MCSD) therapy.72
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There has been an interest in rehabilitation of frail patients 
prior to cardiac transplantation. The placement of an MCSD (to 
aid rehabilitation) in advanced heart failure patients suggests that 
approximately 50% of the patients have an improvement in their 
frailty level, but importantly, the majority of patients would still be 
considered prefrail.73,74 Notably, the heart group did not feel that 
rehabilitation alone was a viable therapeutic option for patients as 
improvement in frailty would be minimal and would expose patients 
to a heightened risk of death. These patients should be considered 
for MCSD therapy, if appropriate, which would enable rehabilita-
tion to proceed. An MCSD would allow for normalization of cardiac 
output, restore end‐organ homeostasis, reverse the catabolic state 
of heart failure, improve muscle mass and eliminate inactivity.
The heart group recognized the critical need for additional ev-
idence to define the ideal frailty measures in heart failure and to 
determine the potential prognostic power of these measures com-
pared to already accepted tools. Nevertheless, given the substan-
tial amount of data surrounding the FFP, it was strongly felt that a 
modification of the FFP was the best measure, at this time, to assess 
frailty in our clinical practice and that it should be included in future 
research investigations. Modifications to the standard FFP include 
the exclusion of weight loss (due to expected volume shifts) and the 
use of the Duke Activity Status Index (DASI) to measure activity. 
Since many patients with end‐stage organ failure are hospitalized 
or critically ill during the transplant evaluation process, a complete 
FFP is not realistic and in these patients, a handgrip strength alone 
should be considered to assess frailty. Although depression and 
cognition are important to consider, the added predictive value of 
these domains needs to be validated further before recommending 
their incorporation into the standard physical frailty assessments.
Key points in heart transplantation:
1. When evaluating patients for heart transplantation or MCSD, a 
modified FFP should be used and is currently the most well‐val-
idated tool.
2. Frailty is at least partially reversible with durable MCSD through 
improved circulation, nutrition and structured rehabilitation 
programs.
TA B L E  2   Suggested tools by organ‐group consensus for assessing areas of frailty
Physical reserve 
measures Strength Nutritional status Social engagement Cognition
Kidney Modified Fried 
Phenotype
SPPB BMI, albumin, Vitamin D levels Kidney Disease 
Quality of Life
MOCA
Liver Liver Frailty Index Liver Frailty Index 
Handgrip 
Muscle mass (skeletal or psoas 
muscle index) Handgrip BMI, 
body composition, and albumin 
are less applicable due to edema 
and underlying hepatic synthetic 
dysfunction
CLDQ Less applicable due to 
hepatic encephalopathy




BMI, body composition, albumin, 
Vitamin D levels
TBA MOCA
Heart Modified Fried 
Phenotype, 6‐min 
walk test, DASI, MLTA
Handgrip Less applicable due to edema TBA MOCA
BMI, body mass index; CDI, Cognitive Depression Index; CLDQ, Chronic Liver Disease Questionnaire; DASI, Duke Activity Status Index; MEP, maxi-
mum expiratory pressure; MIP, maximum inspiratory pressure; MLTA, Minnesota Leisure Time Activities; MOCA, Montreal Cognitive Assessment; 
SPPB, Short Performance Physical Battery; TBA, to be agreed.
Kidney • Exercise
• Physical therapy
• Intergrated inpatient rehabilitation
Liver • Center‐based rehabilitation programs
• BMI‐stratified caloric intake targets (20 to 40 kcal/kg/day)
• Targeted protein intake (1.2‐1.5 g/kg/day)
• Exercise
Lung • Nutrition supplementation
• Physical therapy
• Pulmonary rehabilitation
• Intervention by social workers/psychologists
Heart • Nutrition supplementation
• Exercise
• Physical rehabilitation
• Mechanical circulatory support device
TA B L E  3   Possible Interventions for 
Optimizing Frail Transplant Candidates 
Interventions
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3. A multi‐center Frailty in Advanced Heart Disease Consortium should 
be developed to assess the relationship between the proposed frailty 
measures and outcomes. Patient‐reported outcomes such as quality 
of life after an intervention (eg, MCSD implantation or heart trans-
plantation) are important and should be collected serially.
5  | SUMMARY
Accurately gauging the prevalence of frailty in end‐stage organ failure 
populations is challenging. There is significant overlap between the fea-
tures of organ failure and the signs of frailty (eg, patients with cirrhosis 
and refractory ascites; patients with recurrent heart failure exacerba-
tion). Tools for assessing physical activity in the general population, 
such as the Minnesota Leisure Time Activity scale are unable to make 
this distinction. Therefore, a multidimensional tool that incorporates 
objective and dynamic measures of frailty and allows for assessment 
of potential interventions is needed for individuals with organ failure.
A single frailty tool for all solid organ transplant patients would 
be ideal but might be unrealistic. Although there was agreement that 
frailty is a multi‐dimensional construct, certain aspects were consid-
ered more important in some solid organ populations compared to 
others. For example, whereas cognitive function may be important 
in patients with advanced heart disease, altered cognition may sim-
ply reflect transient hepatic encephalopathy in patients with cirrhosis. 
Unexplained weight loss is another example. A patient with advanced 
CKD may experience significant weight loss after starting hemodialy-
sis whereas a heart failure patient might experience weight gain from 
fluid retention. Neither of these states is related to frailty. Table 2 sum-
marizes potential assessment tools for frailty components as discussed 
in each organ group. It is clear that there is no consensus as yet on how 
to define frailty across organ systems and the assessment tools listed 
would require validation in a prospective cohort. Interventions to re-
verse frailty also varied among organ groups, albeit with some overlap. 
Table 3 summarizes proposed interventions for each organ group.
Despite these challenges, there are metrics that are common to 
all patients with end‐stage organ disease. Core components might 
include handgrip strength and chair stands, both of which were 
identified as important components of frailty in the preconference 
survey. Sarcopenia also appears to have clinical implications with the 
degree of frailty and might be included as an additional metric. These 
components would enable comparisons among cohorts, identifica-
tion of common associations with transplant‐related outcomes, and 
development of transplant‐wide rehabilitation programs.
Research is underway to develop organ‐specific frailty scores 
such as the Liver Frailty Index2 for patients with cirrhosis awaiting 
liver transplantation or the Essential Frailty Toolset for older adults 
with advanced aortic valve disease undergoing valve replacement75 
(which has not yet been applied to the heart transplant setting). A list 
of proposed future research is presented in Table 4.
6  | CONCLUSION
Frailty is a common entity in patients with end‐stage organ disease. 
There is universal consensus that frailty is a useful concept in evalu-
ating candidates for solid organ transplantation. Frailty is known to 
impact both mortality on the waitlist as well as in the posttransplant 
period. The optimal methods to measure frailty are yet to be deter-
mined but studies are underway. Interventions to reverse frailty vary 
among organ groups and some strategies appear promising. This 
conference achieved its intent to highlight the importance of frailty 
in organ transplantation and to plant the seeds for further discussion 
and research in this field.
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TA B L E  4   Areas for future research
• Comparing frailty metrics for patient outcomes on the waiting list
• Determining whether interventions that improve pretransplant 
frailty also improve waitlist outcomes as well as outcomes after 
transplant
• Understanding the role of cognition in the frail phenotype in 
transplant candidates
• Measuring frailty and its prognostic value in the peri‐transplant 
period
• Identifying novel measures of frailty such as biomarkers, imaging 
and body composition analysis
• Coordinating trials of nutritional supplementation via oral/enteral 
feeding or total parenteral nutrition
• Serially collecting patient‐reported outcomes such as quality of 
life
• Further assessing measures of cognition and sarcopenia
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